HIGHBuilt-in & outside partyProduct / Revenue mix
ARCALYST
“10-K Item 1A: 'ARCALYST, our sole product, for the treatment of recurrent pericarditis in the United States, where we derive substantially all of our revenue'”
KNSA · Concentration risk · 10-K extracted
Kiniksa Pharmaceuticals Interna (KNSA) concentration risks
Updated
The most significant concentration Kiniksa Pharmaceuticals Interna discloses is ARCALYST, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Kiniksa Pharmaceuticals Interna’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
Regeneron
“10-K Item 1: 'Regeneron currently manufactures and supplies all of our requirements of ARCALYST for development and commercial activities'”
HIGHBuilt-inGeographic
United States
“10-K Item 1A: 'the United States, where we derive substantially all of our revenue'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile is among the most concentrated disclosed in the filing universe: all three identified exposures carry a large disclosed share, and they are mutually reinforcing rather than diversifying. The revenue base is entirely dependent on a single product, ARCALYST, which is described as the sole product and the source of substantially all of the company's revenue, a large-share mixed exposure combining structural positioning in the recurrent pericarditis indication with the inherent dependency risks of a single-product franchise. Any event threatening ARCALYST's commercial position — competitive entry, label change, or reimbursement disruption — would affect virtually all revenue. Layered on the single-product exposure is a sole-supplier dependency: Regeneron currently manufactures and supplies all of the company's requirements of ARCALYST for both development and commercial activities, a large disclosed share and pure dependency in character. There is no alternative manufacturer, meaning any interruption to the Regeneron supply relationship would directly impair the ability to supply patients and generate revenue. The combination of a single product and a single manufacturer for that product creates a doubly concentrated supply-side risk. The geographic exposure compounds the picture: the company derives substantially all of its revenue from the United States, a large structural share. International revenues are not a meaningful offset. Together, all three concentrations point in the same direction — single product, single supplier, single geography — making this a highly concentrated profile where diversification across any of the three dimensions is the primary watch item for long-term risk reduction.
For the engine’s reasoning on KNSA’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - Specialty & Generic
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| KNSA● | Kiniksa Pharmaceuticals Interna | 3 | 0 | 0 | 3 |
| ANIP | ANI Pharmaceuticals, Inc. | 2 | 1 | 0 | 3 |
| AMLX | Amylyx Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| AMRX | Amneal Pharmaceuticals, Inc. | 1 | 1 | 0 | 2 |
| BCRX | BioCryst Pharmaceuticals, Inc. | 0 | 2 | 0 | 2 |
| ALKS | Alkermes plc | 0 | 1 | 1 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.